SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Three U.S. patent applications were published covering novel combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine, generated through the ongoing collaboration with Clearmind Medicine. The applications target potential therapies for depression, PTSD, pain and substance use disorders, building on a prior application covering MDMA-PEA combinations.
Key figures
- Covered compounds
- ["LSD","ketamine","ibogaine"]
- Patent applications published
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.